patients to their pre-inhibitor baseline state, but is costly, timeconsuming and not uniformly successful. 5, 6 Assays to accurately determine the presence of a specific FVIII inhibitor are therefore essential for clinical management of patients.
In haemophilia patients, the antibody response against FVIII is polyclonal involving multiple IgG subclasses. Previous studies have demonstrated that IgG1 and IgG4 are the most common anti-FVIII antibody subclasses present in NBA-positive samples. 3, 7, 8 Anti-FVIII IgG4 is found almost exclusively in patients with functional FVIII inhibitors, whereas anti-FVIII IgG1 is also common in patients without functional inhibitors and has been suggested to be predictive of inhibitor development. 3, 5, 8 Hofbauer et al 8 have
detected high-affinity anti-FVIII IgG1 and anti-FVIII IgG4 antibodies in haemophilia patients over 500 days before the first detection of a FVIII inhibitor by traditional methods. As the relative abundance of IgG4 is the lowest of all of IgG subclasses in human serum, 9 the exclusivity of anti-FVIII IgG4 to an evolving inhibitor or inhibitor-positive sample makes it a compelling marker for FVIII inhibitors.
Unlike specific haemophilic inhibitors, nonspecific inhibitors of coagulation do not directly neutralize FVIII or FIX activity but instead interfere with assays measuring coagulation factor levels, independent of FVIII or FIX function. 10, 11 The archetypical nonspecific factor inhibitor is the lupus anticoagulant (LA), which was reported in 21% of HA patients. 12 A LA, through its phospholipid binding, can interfere with measurement of FVIII-specific inhibitors in clot-based assays, 10, 11, 13 resulting in false-positive FVIII inhibitor titres. 13, 14 Conversely, FVIII inhibitors are reported to interfere with LA assays, producing false-positive results for those tests. 15, 16 Currently no single laboratory test, such as Dilute Russell's Viper Venom Time (DRVVT), APTT-LA, Staclot-LA or Dilute Protime, definitively identifies all LAs. 12, 14, 15 As patients with HA may develop a LA in response to common stimuli, including infection, a subset of HA patients may carry both types of antibodies; however, as baseline coagulation assays such as the APTT are prolonged in haemophilia patients, a LA may go unnoticed unless specific studies are performed. Distinguishing a LA from a specific factor neutralizing inhibitor has important implications for research, surveillance and clinical management of patients with haemophilia. 3, 13 In clinical trials and surveillance programs, falsepositive specific factor inhibitor results may contribute to erroneous prevalence and incidence calculations, and mischaracterization of patients. 13 In the clinical setting, interference by LAs makes it difficult to identify specific factor inhibitors, which is critically important to determine appropriate therapy.
Although assays to identify a specific FVIII inhibitor, without interference from non-specific inhibitors of coagulation, have been proposed, 15,17 they require validation. In this observational study, we tested samples from haemophilia and non-haemophilic subjects to determine whether the NBA, CBA or fluorescence immunoassay (FLI) could discriminate between a LA and a specific FVIII inhibitor. Over a 4-year period, blood samples were collected with informed consent from subjects with HA and a diagnosis of a specific FVIII inhibitor; subjects with a suspected or confirmed LA with an underlying diagnosis of HA; and subjects with a LA, but without an underlying diagnosis of haemophilia. The IHTC subjects were followed for 1-year following closure of the study to determine further changes in inhibitor status. 
| MATERIAL S AND ME THODS

| Subjects
| FVIII inhibitor testing
The NBA and CBA were performed at CDC as previously described 13 with positive NBA and CBA results defined as ≥0.5 NijmegenBethesda units (NBU) and chromogenic Bethesda Units (CBU), respectively. The coefficients of variation (CV) for the NBA and CBA were 9.8% and 5.9% for a negative control and 10.2% and 6.9% for a 1 NBU positive control, respectively.
| Anti-FVIII antibody testing
FLI was performed at the CDC as previously described. 3 The threshold for positivity was set at 2 standard deviations above of Innovin (50 μl, Siemens) in Owrens Veronal Buffer (Siemens). After incubation for 3 minutes at 37°C, CaCl 2 (50 μl, Siemens) was added and clot time was recorded and compared to the normal range for the dPT assay. Quality control for the dPT assay was performed using a normal and weak lupus positive control. Table 1 shows the demographics of the haemophilia study group. AA, African American; C, Caucasian; NH, non-Hispanic; NA, not applicable. All subjects had severe haemophilia A. The inhibitor risk is based on a literature search of that specific mutation being known to increase the risk of an inhibitor. Reported indicates that there are literature data to indicate that an inhibitor is associated with that mutation. Unreported indicates that that mutation was not known to be associated with an increased inhibitor risk in the literature or other databases. Samples were reviewed from: (i) The haemophilia reference group (a summary of previously published data for a group of 97 haemophilia A patients tested as part of the Hemophilia Inhibitor Research Study and used for reference); (ii) The haemophilia study group (the study group of 11 haemophilia patients listed in Table 4 ); and (iii) The non-haemophilia study group (the study group of 41 non-haemophilia patients with positive LA tests).
| RE SULTS
TA B L E 2 Results of factor VIII (FVIII) inhibitor tests by
of 97 subjects collected during HIRS. 13 NBA-negative subjects in the haemophilia reference group had no history of an inhibitor. Eight of 11 subjects in the haemophilia study group had a prior history of ITI therapy or received ITI during the study. and (iii) samples with a positive CBA titre. The "All HA" group is the haemophilia study group; and the "All LA" is the non-haemophilia study group. The "HA/NBA" and "LA/NBA" columns reflect only samples with positive NBA titres; and the "HA/CBA" and "LA/CBA" columns reflect only samples with positive CBA titres F I G U R E 2 Longitudinal analyses of 3 subjects receiving ITI.
Results for anti-FVIII IgG4 (MFI), NBA (NBU) and CBA (CBU) are plotted over time using time, t = 0 for the subject's initial study sample. All anti-FVIII IgG4 results were positive for subjects H4 and H6. NBA and CBA titres varied, giving positive and negative readings at different timepoints-but neither subject was successfully tolerized during the study or 1-year follow-up period. Subject H8 initially had a negative anti-FVIII IgG4, which became positive during the course ITI of ITI therapy. At the final timepoint, subject H8 was considered tolerized, which was reflected in his negative anti-FVIII IgG4, NBA and CBA results and he has remained tolerized during the 1-y post-study follow-up period CBA result. One CBA-positive patient had titres of 0.5 CBU and 0.2 NBU; while the other had titres 0.8 CBU and 0.3 NBU. Table 3 compares anti-FVIII IgG and IgM results for these subjects to the non-heamophilia reference group (previously published data for a paid group of non-haemophilia subjects). 3 There was no correlation between individual LA test positivity and either NBA, CBA or FLI result (Table S1 ).
Test results from the 11 subjects in the haemophilia study group are listed in Table 4 
| D ISCUSS I ON
To determine appropriate management for patients with inhibitors, clinicians rely on composite assessment of clinical history, bleeding manifestations and inhibitor titre as measured by functional assays; however, LAs are known to cause false-positive results in the NBA. 12, 13 This problem is exacerbated by the lack of a definitive diagnostic test for LAs and by documented inconsistencies in laboratory testing for FVIII inhibitors. 19, 20 The CBA is less influenced by a LA than the NBA or BA; and anti-FVIII IgG1 and anti-FVIII IgG4 subtypes have been shown to correlate better with detection of a neutralizing haemophilic inhibitor by CBA than by NBA.
5,13
The current study aimed to improve understanding of the effect of a LA on different FVIII inhibitor assays. Our hypothesis was that the immunoreactive profile generated by anti-FVIII FLI could be used to distinguish a haemophilia patient with a LA from a haemophilia patient with a clinically relevant FVIII inhibitor.
The discriminatory value of the anti-FVIII IgG4 assay for distinguishing LAs from FVIII inhibitors is supported by our data which show that none of the 41 samples from the non-haemophilia study group (with positive LA tests)-including those with either a positive NBA or CBA titre-were positive in the anti-FVIII IgG4 assay.
These results are similar to those observed in healthy subjects by Whelan et al 7 using an ELISA and by Boylan et al using the FLI. The negative results in the FLI strongly support our hypothesis that this assay is unaffected by the presence of Las, whereas the commercial anti-FVIII ELISA, which is reported to measure IgG but is not specific for IgG4, has been reported to give positive results in some LA patients. 21 Our results show IgG subclasses other than IgG4 may be present in LA patients and could influence results of this ELISA test.
Our data suggest that a specific anti-FVIII IgG4 assay is able to discern a LA from a low-titre FVIII inhibitor with a high discriminatory value, while anti-FVIII IgG1, IgG2, IgG3 and IgGM are less useful.
The observation that 12 (29%) LA-positive samples from the nonhaemophilia study group were positive in the NBA and 2 (5%) in the CBA in the absence of anti-FVIII IgG4 confirm that these functional assays may be subject to interference.
Data from the haemophilia reference group show a low incidence of anti-FVIII IgG4 antibodies in subjects with a negative NBA (similar to the non-haemophilia reference group) and a high incidence in NBA-positive samples. There are limitations inherent to this study: most noticeably, the study evaluated a relatively limited number of subjects and samples, and may not be representative of the broader inhibitor population; secondly, recommended repeat LA assay results were not consistently available to confirm presence of a LA, which could potentially impact some of the observed trends; and thirdly, the FLI assay cannot distinguish a low affinity from a high affinity antibody, and so might record a positive result in the absence of a clinically relevant inhibitor.
This study demonstrates the clinical utility of immunologic testing for distinguishing specific anti-FVIII antibodies from LA. A high correlation exists between the previously recommended CBA and the anti-FVIII IgG4 FLI assay, which has a more rapid turn-around time and is less expensive to perform. While cost, delays and uncertainty associated with additional assays may be high, the cost of repeat patient visits, testing and unnecessary therapy is far greater.
Based on our observations, we recommend that all samples with low-titre haemophilic inhibitors or with potential LAs are screened in immunologic assays. Recognizing that our data set is relatively small, we further recommend that a prospective study be initiated to further investigate the role of FLI in distinguishing haemophilic inhibitors from interfering LAs.
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